Chemotherapy for advanced non-small-cell lung cancer: Who, what, when, why?
Chemotherapy for advanced non-small-cell lung cancer: Who, what, when, why?
复制标题
DOI：
10.1200/jco.2002.07.059
复制
发表时间：
2002-09-15
影响因子：
45.3
通讯作者：
Bunn, PA
中科院分区：
文献类型：
--
作者：
Bunn, PA
尽管晚期（IIIB期伴胸腔积液或IV期）非小细胞肺癌患者的生存率较低，但与旧的基于顺铂的治疗相比，新化疗药物的引入改善了生存率和生活质量，降低了毒性。随机试验支持在所有年龄段的体能状态为0至1的患者中使用两种药物组合。这些两种药物组合应至少包含一种新药物。这些两种药物组合中的一些在选定的体能状态为2的患者中可能是可接受的。较新的靶向治疗有望在不增加大量额外毒性的情况下改善结果。
Despite the poor survival of patients with advanced (stage IIIB with pleural effusion or stage IV) non-small-cell lung cancer, the introduction of new chemotherapeutic agents has improved survival and quality of life with reduced toxicity compared with older cisplatin-based therapies. Randomized trials support the use of two-drug combinations for patients of all ages with performance status of 0 to 1. These two-drug combinations should contain at least one new agent. Some of these two-drug combinations may be acceptable in selected patients with a performance status of 2. Newer, targeted therapies hold promise to improve outcome without adding a great deal of additional toxicity.